Paxman publishes newsletter on the approval of an upcoming study with the company’s scalp cooling system in South Korea

20 October 2020 - 14:45

Today, Paxman publishes the October issue of its newsletter aimed at shareholders, investors and other interested parties.

This issue highlights the South Korean Ministry of Food and Drug Safety (MFDS) approval of a trial with Paxman’s PSCS system in South Korea to evaluate its effectiveness in reducing permanent chemotherapy-induced alopecia in woman with breast cancer. The trial will begin to recruit patients in November 2020.

The newsletter also includes information on several new system orders and installs in the United States and the Netherlands, the growing US foundation support for Paxman’s scalp cooling and the company’s busy virtual event schedule for the fourth quarter of 2020.

To read the newsletter and subscribe for upcoming issues, follow this link:

PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Provided by: MFN
Nasdaq First North GM (Sweden)
Paxman AB
Paxman AB is a Sweden based company engages in the development of PAXMAN Scalp Cooling System that is used to minimize hair loss in connection with chemotherapy treatment. The company offers a stand-alone, mobile electric cooling unit, which is a liquid-based cooling system that cools down the patient's scalp through the silicone hat. Geographically the company markets its product to Great Britain...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date